| Literature DB >> 34400329 |
Xin He1, Jianming Liu2, Fei Gu2, Jinghai Chen3, Yao Wei Lu2, Jian Ding2, Haipeng Guo4, Mao Nie5, Masaharu Kataoka6, Zhiqiang Lin2, Xiaoyun Hu2, Huaqun Chen7, Xinxue Liao8, Yugang Dong8, Wang Min9, Zhong-Liang Deng5, William T Pu10, Zhan-Peng Huang11, Da-Zhi Wang12.
Abstract
Heart failure is a leading cause of fatality in Duchenne muscular dystrophy (DMD) patients. Previously, we discovered that cardiac and skeletal-muscle-enriched CIP proteins play important roles in cardiac function. Here, we report that CIP, a striated muscle-specific protein, participates in the regulation of dystrophic cardiomyopathy. Using a mouse model of human DMD, we found that deletion of CIP leads to dilated cardiomyopathy and heart failure in young, non-syndromic mdx mice. Conversely, transgenic overexpression of CIP reduces pathological dystrophic cardiomyopathy in old, syndromic mdx mice. Genome-wide transcriptome analyses reveal that molecular pathways involving fibrogenesis and oxidative stress are affected in CIP-mediated dystrophic cardiomyopathy. Mechanistically, we found that CIP interacts with dystrophin and calcineurin (CnA) to suppress the CnA-Nuclear Factor of Activated T cells (NFAT) pathway, which results in decreased expression of Nox4, a key component of the oxidative stress pathway. Overexpression of Nox4 accelerates the development of dystrophic cardiomyopathy in mdx mice. Our study indicates CIP is a modifier of dystrophic cardiomyopathy and a potential therapeutic target for this devastating disease.Entities:
Keywords: CIP; Duchenne muscular dystrophy; Nox4; calcineurin; dystrophic cardiomyopathy; fibrosis; oxidative stress
Mesh:
Substances:
Year: 2021 PMID: 34400329 PMCID: PMC8822131 DOI: 10.1016/j.ymthe.2021.08.022
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454